Cargando…

MiR-34a and miR-206 act as novel prognostic and therapy biomarkers in cervical cancer

BACKGROUND: Recent evidence indicated that the aberrant expression of microRNA plays a crucial role in the development of cervical cancer. The overall shorter survival was strongly related to the abnormal expression of microRNA-34a (miR-34a) and microRNA-206 (miR-206), which target B cell lymphoma-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ai-Hua, Qin, Yu-E, Tang, Wen-Fan, Tao, Jing, Song, Hua-mei, Zuo, Manzhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466768/
https://www.ncbi.nlm.nih.gov/pubmed/28615991
http://dx.doi.org/10.1186/s12935-017-0431-9
_version_ 1783243157014577152
author Chen, Ai-Hua
Qin, Yu-E
Tang, Wen-Fan
Tao, Jing
Song, Hua-mei
Zuo, Manzhen
author_facet Chen, Ai-Hua
Qin, Yu-E
Tang, Wen-Fan
Tao, Jing
Song, Hua-mei
Zuo, Manzhen
author_sort Chen, Ai-Hua
collection PubMed
description BACKGROUND: Recent evidence indicated that the aberrant expression of microRNA plays a crucial role in the development of cervical cancer. The overall shorter survival was strongly related to the abnormal expression of microRNA-34a (miR-34a) and microRNA-206 (miR-206), which target B cell lymphoma-2(Bcl2) and c-Met. Hepatocyte growth factor (HGF)/c-Met pathway is related to the occurrence, development and prognosis of cervical cancer, and c-Met is significantly overexpressed in cervical squamous cell carcinoma. Bcl2 is also considered to be a promising target for developing novel anticancer treatments. METHODS: In this study, we detect the expression of miR-34a and miR-206 in the cervical cancer tissue through quantificational real-time polymerase chain reaction (qRT-PCR) assay, and the expression of Bcl2 and c-Met from cervical cancer tissue were detected by immunohistochemistry. RESULTS: The expression of miR-34a and miR-206 were down-regulated in the cervical cancer tissue through qRT-PCR assay. As target genes of miR-34a and miR-206, Bcl2 and c-Met were up-regulated in cervical cancer tissues through qRT-PCR assay and immunohistochemistry. Kaplan–Meier and log-rank analysis revealed that down-regulated expression of miR-34a and miR-206 were strongly related to shorter overall survival. Multivariate Cox proportional hazards model for all variables that were statistically significant in the univariate analysis demonstrated that miR-34a (P = 0.038) and miR-206 (P = 0.008) might be independent prognostic factors for overall survival of patients suffering from cervical cancer. CONCLUSIONS: The up-regulation of Bcl2 and c-Met promotes the cervical cancer’s progress, and the expression of miR-34a and miR-206 significantly correlated with the progression and prognosis in cervical cancer. All of these suggested that miR-34a and miR-206 might be the novel prognostic and therapy tools in cervical cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12935-017-0431-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5466768
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54667682017-06-14 MiR-34a and miR-206 act as novel prognostic and therapy biomarkers in cervical cancer Chen, Ai-Hua Qin, Yu-E Tang, Wen-Fan Tao, Jing Song, Hua-mei Zuo, Manzhen Cancer Cell Int Primary Research BACKGROUND: Recent evidence indicated that the aberrant expression of microRNA plays a crucial role in the development of cervical cancer. The overall shorter survival was strongly related to the abnormal expression of microRNA-34a (miR-34a) and microRNA-206 (miR-206), which target B cell lymphoma-2(Bcl2) and c-Met. Hepatocyte growth factor (HGF)/c-Met pathway is related to the occurrence, development and prognosis of cervical cancer, and c-Met is significantly overexpressed in cervical squamous cell carcinoma. Bcl2 is also considered to be a promising target for developing novel anticancer treatments. METHODS: In this study, we detect the expression of miR-34a and miR-206 in the cervical cancer tissue through quantificational real-time polymerase chain reaction (qRT-PCR) assay, and the expression of Bcl2 and c-Met from cervical cancer tissue were detected by immunohistochemistry. RESULTS: The expression of miR-34a and miR-206 were down-regulated in the cervical cancer tissue through qRT-PCR assay. As target genes of miR-34a and miR-206, Bcl2 and c-Met were up-regulated in cervical cancer tissues through qRT-PCR assay and immunohistochemistry. Kaplan–Meier and log-rank analysis revealed that down-regulated expression of miR-34a and miR-206 were strongly related to shorter overall survival. Multivariate Cox proportional hazards model for all variables that were statistically significant in the univariate analysis demonstrated that miR-34a (P = 0.038) and miR-206 (P = 0.008) might be independent prognostic factors for overall survival of patients suffering from cervical cancer. CONCLUSIONS: The up-regulation of Bcl2 and c-Met promotes the cervical cancer’s progress, and the expression of miR-34a and miR-206 significantly correlated with the progression and prognosis in cervical cancer. All of these suggested that miR-34a and miR-206 might be the novel prognostic and therapy tools in cervical cancer. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12935-017-0431-9) contains supplementary material, which is available to authorized users. BioMed Central 2017-06-09 /pmc/articles/PMC5466768/ /pubmed/28615991 http://dx.doi.org/10.1186/s12935-017-0431-9 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Primary Research
Chen, Ai-Hua
Qin, Yu-E
Tang, Wen-Fan
Tao, Jing
Song, Hua-mei
Zuo, Manzhen
MiR-34a and miR-206 act as novel prognostic and therapy biomarkers in cervical cancer
title MiR-34a and miR-206 act as novel prognostic and therapy biomarkers in cervical cancer
title_full MiR-34a and miR-206 act as novel prognostic and therapy biomarkers in cervical cancer
title_fullStr MiR-34a and miR-206 act as novel prognostic and therapy biomarkers in cervical cancer
title_full_unstemmed MiR-34a and miR-206 act as novel prognostic and therapy biomarkers in cervical cancer
title_short MiR-34a and miR-206 act as novel prognostic and therapy biomarkers in cervical cancer
title_sort mir-34a and mir-206 act as novel prognostic and therapy biomarkers in cervical cancer
topic Primary Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466768/
https://www.ncbi.nlm.nih.gov/pubmed/28615991
http://dx.doi.org/10.1186/s12935-017-0431-9
work_keys_str_mv AT chenaihua mir34aandmir206actasnovelprognosticandtherapybiomarkersincervicalcancer
AT qinyue mir34aandmir206actasnovelprognosticandtherapybiomarkersincervicalcancer
AT tangwenfan mir34aandmir206actasnovelprognosticandtherapybiomarkersincervicalcancer
AT taojing mir34aandmir206actasnovelprognosticandtherapybiomarkersincervicalcancer
AT songhuamei mir34aandmir206actasnovelprognosticandtherapybiomarkersincervicalcancer
AT zuomanzhen mir34aandmir206actasnovelprognosticandtherapybiomarkersincervicalcancer